Study of phase II, multicenter, open, assessing dasatinib in patients of acute myelogenous leukemia (AML) to core binding factors (CBF) resistant to conventional chemotherapy or molecular relapse.

Trial Profile

Study of phase II, multicenter, open, assessing dasatinib in patients of acute myelogenous leukemia (AML) to core binding factors (CBF) resistant to conventional chemotherapy or molecular relapse.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms DasaCBF
  • Most Recent Events

    • 03 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top